• Treffer 7 von 12
Zurück zur Trefferliste

Analysis of microRNAs in exosomes of breast cancer patients in search of molecular prognostic factors in brain metastases

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-284476
  • Brain metastases are the most severe tumorous spread during breast cancer disease. They are associated with a limited quality of life and a very poor overall survival. A subtype of extracellular vesicles, exosomes, are sequestered by all kinds of cells, including tumor cells, and play a role in cell-cell communication. Exosomes contain, among others, microRNAs (miRs). Exosomes can be taken up by other cells in the body, and their active molecules can affect the cellular process in target cells. Tumor-secreted exosomes can affect the integrityBrain metastases are the most severe tumorous spread during breast cancer disease. They are associated with a limited quality of life and a very poor overall survival. A subtype of extracellular vesicles, exosomes, are sequestered by all kinds of cells, including tumor cells, and play a role in cell-cell communication. Exosomes contain, among others, microRNAs (miRs). Exosomes can be taken up by other cells in the body, and their active molecules can affect the cellular process in target cells. Tumor-secreted exosomes can affect the integrity of the blood-brain barrier (BBB) and have an impact on brain metastases forming. Serum samples from healthy donors, breast cancer patients with primary tumors, or with brain, bone, or visceral metastases were used to isolate exosomes and exosomal miRs. Exosomes expressed exosomal markers CD63 and CD9, and their amount did not vary significantly between groups, as shown by Western blot and ELISA. The selected 48 miRs were detected using real-time PCR. Area under the receiver-operating characteristic curve (AUC) was used to evaluate the diagnostic accuracy. We identified two miRs with the potential to serve as prognostic markers for brain metastases. Hsa-miR-576-3p was significantly upregulated, and hsa-miR-130a-3p was significantly downregulated in exosomes from breast cancer patients with cerebral metastases with AUC: 0.705 and 0.699, respectively. Furthermore, correlation of miR levels with tumor markers revealed that hsa-miR-340-5p levels were significantly correlated with the percentage of Ki67-positive tumor cells, while hsa-miR-342-3p levels were inversely correlated with tumor staging. Analysis of the expression levels of miRs in serum exosomes from breast cancer patients has the potential to identify new, non-invasive, blood-borne prognostic molecular markers to predict the potential for brain metastasis in breast cancer. Additional functional analyzes and careful validation of the identified markers are required before their potential future diagnostic use.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Carolin J. Curtaz, Leonie Reifschläger, Linus Strähle, Jonas Feldheim, Julia J. Feldheim, Constanze Schmitt, Matthias Kiesel, Saskia-Laureen Herbert, Achim Wöckel, Patrick MeybohmORCiD, Malgorzata Burek
URN:urn:nbn:de:bvb:20-opus-284476
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Frauenklinik und Poliklinik
Medizinische Fakultät / Klinik und Poliklinik für Anästhesiologie (ab 2004)
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):International Journal of Molecular Sciences
ISSN:1422-0067
Erscheinungsjahr:2022
Band / Jahrgang:23
Heft / Ausgabe:7
Aufsatznummer:3683
Originalveröffentlichung / Quelle:International Journal of Molecular Sciences (2022) 23:7, 3683. DOI:10.3390/ijms23073683
DOI:https://doi.org/10.3390/ijms23073683
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):blood-brain barrier; breast cancer; breast cancer metastases; exosomes; gene expression; microRNA; patient serum; prognostic marker
Datum der Freischaltung:13.04.2023
Datum der Erstveröffentlichung:27.03.2022
Open-Access-Publikationsfonds / Förderzeitraum 2022
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International